Implications for Practice
triple-negative breast cancer
TRIPLE-NEGATIVE BREAST CANCER
This phase II study showed that talazoparib monotherapy was active with an observed pathologic complete response (pCR) rate of 45.8% in patients with early-stage triple-negative breast cancer and germline 